COMIRNATY LP.8.1 30 mcg/dose 10 ser pré 0.3 ml

7680704030027 CH-70403
COMIRNATY LP.8.1 30 mcg/dose 10 ser pré 0.3 ml
COMIRNATY LP.8.1 30 mcg/dose 10 ser pré 0.3 ml
COMIRNATY LP.8.1 30 mcg/dose 10 ser pré 0.3 ml
1 / 3
google

Details

Product number
-
CPT
-
Packaging group
-
Unit
-

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
28/02/2026
Patient information leaflet
Français
28/02/2026
Patient information leaflet
Italien
28/02/2026
Professional SmPC
Allemand
28/02/2026
Professional SmPC
Français
28/02/2026
Professional SmPC
Italien
28/02/2026

Detailed composition

Substance Quantity Type Category
SUS
30.0 UG Substance Wirkstoff (Principe actif)
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK

Reimbursement information

Public price
CHF 770.65
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/09/2025

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
70403
Drug name
Comirnaty LP.8.1, Injektionsdispersion in einer Fertigspritze
Galenic form
INLFS
ATC Code
J07BN01
Authorization status
Z
Dispensation category
B
First authorization
06/08/2025
Authorization expiration date
05/08/2030
IT number
08.08.
Domain
Human medicine
Field of application
Comirnaty LP.8.1 (30 Mikrogramm)/Dosis gebrauchsfertige Injektionsdispersion ist indiziert für die aktive Immunisierung zur Vorbeugung der durch das SARS-CoV-2-Virus hervorgerufenen COVID-19-Erkrankung bei Personen ab 12 Jahren.

Packaging details

Description (FR)
COMIRNATY LP.8.1 30 Mikrogramm sol inj 30 µg 10 pc
Description (DE)
COMIRNATY LP.8.1 30 Mikrogramm Inj Lös 30 µg 10 St
Market launch
06/08/2025
Narcotic (BTM)
No

Other packaging sizes

COMIRNATY LP.8.1 30 Mikrogramm sol inj 30 µg 1 pce
1 FESP
View